Research Gist
This preclinical study investigated whether the standardized Bacopa monniera extract CDRI-08 could improve recognition memory through changes in hippocampal gene regulation. Male and female Wistar rat pups received 80 mg/kg orally from postnatal Day 15 to Day 29, followed by behavioural and molecular assessments.
Bacopa-treated rats showed better novel-object recognition, alongside reduced methylation and increased expression of reelin, increased unmethylated BDNF promoter DNA, higher BDNF expression, and enhanced activity or interaction of several synaptic-signalling proteins. These findings suggest a possible epigenetic and synaptic pathway behind the observed memory effect, but they do not establish the same mechanism or benefit in humans.
Key Learnings
- The study used 72 male and female Wistar rat pups, divided into control, CDRI-08 and 5-azacytidine comparison groups, with 24 animals per group.
- CDRI-08 was a standardized extract containing 55 ± 5% bacosides, administered orally at 80 mg/kg daily for 15 days.
- Bacopa-treated rats showed a higher novel-object discrimination index, indicating improved recognition-memory performance compared with controls.
- Treatment increased unmethylated reelin-promoter DNA, reduced methylated reelin DNA and increased reelin expression in the hippocampus. Recognition performance correlated with reelin methylation status.
- Unmethylated BDNF-promoter DNA, BDNF messenger RNA and BDNF protein increased, although the measured methylated BDNF fraction did not significantly decrease.
- Bacopa treatment was also associated with greater ApoER2–DAB1–NMDAR signalling and increased interaction of the NR2A receptor subunit with SFK and PSD-95, supporting involvement of synaptic-plasticity pathways.
- This was a developmental rat study using one extract and dose. No dedicated safety assessment or human testing was reported, and the complete causal pathway remains an interpretation based on linked behavioural and molecular findings.
